Last Updated: November 16, 2026

TRUMENBA Drug Profile

« Back to Dashboard


Summary for Tradename: TRUMENBA
High Confidence Patents:10
Applicants:1
BLAs:1
Recent Clinical Trials: See clinical trials for TRUMENBA
Recent Clinical Trials for TRUMENBA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Sanofi Pasteur, a Sanofi CompanyPhase 1/Phase 2

See all TRUMENBA clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRUMENBA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRUMENBA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Wyeth Pharmaceuticals Llc TRUMENBA meningococcal group b vaccine Injection 125549 ⤷  Start Trial 2036-05-16 DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc TRUMENBA meningococcal group b vaccine Injection 125549 ⤷  Start Trial 2034-12-04 DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc TRUMENBA meningococcal group b vaccine Injection 125549 ⤷  Start Trial 2040-10-30 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for TRUMENBA Derived from Patent Text Search

These patents were obtained by searching patent claims

TRUMENBA Market Dynamics and Financial Trajectory

Last updated: November 15, 2026

Trumenba is Pfizer’s recombinant meningococcal group B vaccine for individuals age 10 and older. Its commercial outlook depends on adolescent vaccination adoption, public-health recommendations, outbreak demand, pricing, and competition from GSK’s Bexsero. Pfizer does not separately disclose Trumenba revenue in its recent annual reports, so the product’s financial trajectory must be assessed through portfolio disclosures and market drivers rather than a verified standalone sales series. [1-3]

What is Trumenba and how does it compete in meningococcal B vaccination?

Trumenba contains two recombinant lipidated factor H binding protein variants representing the two major fHbp subfamilies. It is manufactured using recombinant technology and is administered as either a two-dose or three-dose series, depending on the schedule and patient risk profile. [4]

The principal competitor is Bexsero, marketed by GSK. Both products target serogroup B meningococcal disease, but they use different antigen designs:

Attribute Trumenba Bexsero
Manufacturer Pfizer GSK
Product type Recombinant protein vaccine Multicomponent recombinant vaccine
Primary antigen strategy Two fHbp variants Four antigen components
U.S. age range 10 years and older 10 through 25 years under the original U.S. indication
Dosing Two or three doses, depending on schedule Two doses for most eligible adolescents and young adults
U.S. regulatory pathway Biologics license application Biologics license application
Primary demand segments Adolescents, young adults, high-risk individuals, outbreak populations Same broad market segments
Direct biosimilar exposure Low Low

The products are not interchangeable at the antigen or brand level. CDC guidance does not recommend switching between MenB vaccine brands during a series unless the original product is unavailable. [5]

What is the FDA regulatory status of Trumenba?

The FDA first approved Trumenba in October 2014 for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. [6]

In 2016, the FDA approved a two-dose schedule for healthy adolescents and young adults. A three-dose schedule remains relevant for individuals at increased risk, including people with persistent complement component deficiencies, people receiving complement inhibitors, individuals with anatomic or functional asplenia, microbiologists routinely exposed to N. meningitidis, and people identified during an outbreak. [4,7]

The FDA later expanded Trumenba’s U.S. age indication to individuals 10 years and older. This broadened the addressable population, although CDC recommendations and payer coverage continue to determine actual utilization. [8]

How does CDC recommend MenB vaccination?

CDC recommends MenB vaccination for certain individuals age 10 years and older who are at increased risk. For healthy adolescents and young adults, vaccination is based on shared clinical decision-making, generally at ages 16 through 23, with ages 16 through 18 preferred. [5]

This recommendation structure limits automatic, population-wide uptake. MenB vaccination is therefore less predictable than vaccines included in routine childhood schedules with universal recommendations.

When does Trumenba lose regulatory exclusivity?

Trumenba received FDA biologics approval in 2014. The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for an original biological product, subject to statutory qualifications. On that basis, the key U.S. reference-product exclusivity milestone falls in 2026. [9]

Regulatory exclusivity does not equal patent expiry. A biologic may remain protected by formulation, manufacturing, antigen, process, or method-of-use patents after regulatory exclusivity expires. Conversely, the expiration of a patent does not automatically produce competitive entry.

Protection category Trumenba assessment
FDA biologics approval October 2014
Reference-product exclusivity Expected to become a major issue around 2026
Orange Book listing Not the relevant principal system for a biologic vaccine
Purple Book relevance Biologic reference-product and biosimilar status
ANDA generic pathway Not applicable
Paragraph IV challenge Not applicable through an ANDA
Biosimilar pathway Legally possible in principle, commercially limited for vaccines
Patent-expiry analysis Requires claim-by-claim review of Pfizer patent families

The FDA Orange Book primarily covers approved drug products submitted through NDAs and ANDAs. Biologic reference products and biosimilar products are tracked through the Purple Book framework. Trumenba should therefore be analyzed through BLA, Purple Book, and patent records rather than through a conventional Orange Book patent-certification strategy. [10,11]

How strong is the Trumenba patent estate?

Trumenba’s protection is likely to rest on a combination of biologic product and manufacturing rights rather than on a single composition-of-matter patent comparable to a small-molecule drug.

Potential protection categories include:

  • fHbp antigen sequences and variants;
  • recombinant expression systems;
  • lipidation and protein production methods;
  • antigen combinations and dosage formulations;
  • adjuvant compositions;
  • methods of preventing serogroup B meningococcal disease;
  • manufacturing, purification, and quality-control processes.

Public FDA materials do not provide a complete patent-family map for Trumenba. The absence of an Orange Book listing also prevents a simple public readout of asserted patents. Patent strength is therefore best characterized as moderate to strong at the technical level, but difficult to quantify without a current worldwide family and claim chart.

The strongest barriers are likely to involve manufacturing know-how, antigen expression, analytical characterization, and regulatory comparability. A competitor would need to demonstrate that its product is sufficiently similar, clinically acceptable, and commercially competitive, even if it avoids Pfizer’s issued claims.

Are generic, biosimilar, or Paragraph IV challenges likely for Trumenba?

A conventional generic launch is not available because Trumenba is a biologic vaccine. An ANDA filer cannot rely on the standard small-molecule generic pathway.

A biosimilar or interchangeable product could theoretically be submitted under the Public Health Service Act. In practice, vaccine biosimilar development faces several commercial barriers:

  1. MenB demand is concentrated in adolescents, young adults, risk groups, and outbreaks.
  2. The eligible population is smaller than the market for routine pediatric vaccines.
  3. Clinical and analytical comparability requirements can be expensive.
  4. Brand differentiation and public-health procurement relationships matter.
  5. The incumbent product has established safety, supply, and provider familiarity.

No major public Trumenba Paragraph IV litigation pathway has been identified because Paragraph IV certifications apply to patents listed for ANDA products. A future biosimilar dispute would more likely involve BLA exclusivity, patent-infringement claims, the patent dance under the BPCIA, and regulatory interchangeability questions.

What is the financial trajectory of Trumenba?

Pfizer’s public financial reporting does not consistently disclose Trumenba as a separate revenue line. The product is included within broader vaccine or other-product reporting, which prevents an independently verified annual sales series. [1-3]

The available financial conclusion is therefore directional:

Financial factor Current effect on Trumenba
Standalone revenue disclosure Limited
Revenue visibility Lower than Pfizer’s separately reported major vaccines
Demand base Adolescent, young-adult, risk-group, and outbreak vaccination
Price realization Influenced by private insurance, public programs, and institutional purchasing
Volume growth Dependent on recommendation changes and vaccination completion
Competitive pressure Bexsero is the main branded competitor
Margin profile Supported by biologic manufacturing complexity, but exposed to low volumes
Revenue volatility Higher during outbreaks and public-health campaigns
Long-term risk Potential competition after biologic exclusivity and patent barriers weaken

Trumenba is strategically important as part of Pfizer’s vaccine portfolio, but it is not comparable in reported revenue scale to Prevnar, Comirnaty, or other separately disclosed Pfizer franchises. The product’s economics are likely more sensitive to market-share shifts and procurement wins than to broad pharmaceutical prescription growth.

What drives Trumenba revenue growth?

The main growth drivers are:

  • expansion of the eligible age range;
  • increased physician adoption of shared clinical decision-making;
  • higher completion rates for multi-dose schedules;
  • college and university vaccination initiatives;
  • public-health responses to campus or community outbreaks;
  • increased vaccination among immunocompromised and other high-risk patients;
  • improved payer coverage;
  • reduced vaccine hesitancy among adolescents and young adults.

The most important structural constraint is that CDC does not recommend MenB vaccination universally for every adolescent. Shared clinical decision-making creates a large eligible population but does not produce automatic coverage.

What competitive forces affect Trumenba and Bexsero?

Bexsero is the principal branded competitor. Competition occurs through product availability, dosing convenience, contracting, provider preference, public-health procurement, and perceived breadth of protection.

Competitive variable Trumenba implication
Two-dose schedule Supports convenience for routine adolescent use
Three-dose schedule Supports use in higher-risk populations
Brand familiarity Pfizer has broad vaccine distribution capabilities
Antigen design Differentiates Trumenba from Bexsero but does not eliminate competition
Outbreak supply Manufacturing capacity and inventory become critical
Public procurement Contracting can shift volume quickly
Clinical guidance Shared decision-making limits predictable demand
Product switching Lack of routine interchangeability protects brand continuity

Meningococcal disease is rare, which limits the commercial value of efficacy comparisons based on clinical endpoint events. Product selection is more likely to depend on immunogenicity data, schedule, supply, contracting, and institutional practice.

What manufacturing and intellectual-property barriers protect Trumenba?

Trumenba uses recombinant protein technology rather than a conventional polysaccharide-conjugate design. Manufacturing requires control of antigen expression, lipidation, purification, formulation, sterility, potency, and lot consistency. These requirements create operational barriers even if a competitor avoids Pfizer’s patent claims.

The manufacturing estate may be more commercially important than any single patent. A follow-on manufacturer would need to reproduce a complex biological process or develop a different process that produces a clinically comparable product. Regulatory authorities may accept process differences, but the sponsor must establish product quality and clinical performance.

Geographic protection is likely to vary by patent family and national prosecution history. U.S. protection, European protection, and rights in major vaccine markets should be reviewed separately. Patent expiry in one jurisdiction would not authorize launch in another jurisdiction where a valid claim remains in force.

What litigation and settlement risks affect Trumenba?

Trumenba has no conventional generic-entry litigation profile because it is not an ANDA product. The principal legal risks are:

  • patent litigation involving recombinant antigen or manufacturing claims;
  • biosimilar litigation after a future BLA submission;
  • regulatory disputes over interchangeability or labeling;
  • product-liability litigation;
  • supply and contracting disputes;
  • patent challenges by vaccine competitors using alternative antigen designs.

No major publicly established Trumenba settlement agreement comparable to a high-profile small-molecule generic settlement is central to its current market outlook. Any future agreement would need to be evaluated against the product’s regulatory exclusivity date, remaining patent terms, and the competitive position of Bexsero.

What generic launch scenarios exist for Trumenba?

The most realistic scenarios are:

Scenario 1: Continued branded competition

Pfizer and GSK remain the principal commercial suppliers. Market share changes through contracting, supply, dosing preferences, and recommendation-driven demand. This is the base case.

Scenario 2: Post-exclusivity biosimilar development

A follow-on biologic sponsor enters after the statutory and patent barriers weaken. The probability is limited by the modest market size and the technical complexity of MenB vaccine comparability.

Scenario 3: Alternative vaccine technology

A new MenB vaccine with broader antigen coverage, fewer doses, or a more favorable public-health recommendation could reduce Trumenba demand without being a biosimilar.

Scenario 4: Outbreak-driven revenue acceleration

A university, regional, or national outbreak could temporarily increase orders. This would create volume upside but not necessarily a durable change in baseline demand.

What is the revenue exposure for Pfizer?

Trumenba is unlikely to represent a material share of Pfizer’s consolidated revenue compared with its largest vaccine and pharmaceutical products. Its financial value is more relevant at the franchise and portfolio level:

  • it broadens Pfizer’s adolescent and young-adult vaccine presence;
  • it provides exposure to outbreak and high-risk vaccination demand;
  • it adds a differentiated recombinant vaccine platform;
  • it supports Pfizer’s position in institutional vaccine procurement;
  • it contributes incremental revenue after the original MenB market became established.

Because Pfizer does not provide a consistent standalone Trumenba revenue figure, investors should not infer a precise product-level revenue trajectory from Pfizer’s total vaccine reporting. The most defensible view is that Trumenba is a smaller, mature vaccine asset with upside from indication expansion and public-health adoption, but with limited visibility and meaningful competitive exposure.

Key Takeaways

  • Trumenba is Pfizer’s recombinant MenB vaccine for individuals age 10 and older.
  • Bexsero is the main branded competitor.
  • FDA approval began in 2014, with later dosing and age expansions.
  • Reference-product biologic exclusivity is expected to become a key issue around 2026.
  • The Orange Book is not the primary patent-information source for Trumenba; Purple Book and patent records are more relevant.
  • Conventional generic entry and Paragraph IV litigation do not apply.
  • Biosimilar entry is legally possible but commercially less likely than ordinary small-molecule generic entry.
  • Pfizer does not separately disclose a reliable Trumenba revenue series in recent annual reports.
  • Revenue depends heavily on shared clinical decision-making, institutional procurement, outbreak demand, and competition with Bexsero.
  • Manufacturing complexity and process know-how may be stronger practical barriers than any single publicly visible patent.

FAQs About Trumenba Market and Exclusivity

Is Trumenba interchangeable with Bexsero?

No. Trumenba and Bexsero are separate MenB vaccine products with different antigen compositions. CDC guidance generally recommends completing a series with the same brand.

Does Trumenba have an Orange Book patent listing?

The Orange Book is not the principal FDA patent system for biologic vaccines. Trumenba should be evaluated through its BLA, Purple Book status, and underlying U.S. and international patent families.

Can a generic company make a generic version of Trumenba?

Not through the standard ANDA pathway. A follow-on sponsor would need to pursue a biologic pathway, most likely under the biosimilar provisions of the Public Health Service Act.

Why are Trumenba sales difficult to estimate?

Pfizer does not consistently disclose Trumenba revenue as a standalone product line. Public reporting groups it within broader vaccine or other-product categories.

What would most increase Trumenba revenue?

The strongest potential drivers are broader routine recommendations, improved completion of adolescent dosing, increased use in high-risk populations, institutional contracting, and outbreak-related vaccination campaigns.

References

  1. Pfizer Inc. (2024). 2023 annual report. Pfizer.
  2. Pfizer Inc. (2025). 2024 annual report. Pfizer.
  3. Pfizer Inc. (2023). 2022 annual report. Pfizer.
  4. Pfizer Inc. (2024). Trumenba prescribing information. U.S. Food and Drug Administration.
  5. Centers for Disease Control and Prevention. (2024). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2024. CDC.
  6. U.S. Food and Drug Administration. (2014). FDA approves vaccine to prevent serogroup B meningococcal disease. FDA.
  7. Centers for Disease Control and Prevention. (2023). Meningococcal vaccination: Who needs it and when. CDC.
  8. U.S. Food and Drug Administration. (2024). Trumenba supplemental biologics license application and labeling updates. FDA.
  9. U.S. Food and Drug Administration. (2024). Reference product exclusivity for biological products. FDA.
  10. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
  11. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.